Apr 10, 2017 12:04 pm UTC| Business
HAYWARD, Calif., April 10, 2017 -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients...
Apr 10, 2017 12:04 pm UTC| Business
HAYWARD, Calif., April 10, 2017 -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients...
Apr 10, 2017 12:04 pm UTC| Business
LAS VEGAS, April 10, 2017 -- THC Therapeutics (OTC:THCT) is a publicly traded health and healing cannabis company. We are excited to announce that we have accomplished the first step of our stated plans for the growth...
Apr 10, 2017 12:04 pm UTC| Business
HAYWARD, Calif., April 10, 2017 -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients...
Apr 10, 2017 12:04 pm UTC| Business
HAYWARD, Calif., April 10, 2017 -- Anthera Pharmaceuticals. (Nasdaq:ANTH) today announced the completion of dosing in the randomized, double-blind, placebo controlled, Phase 2 BRIGHT-SC study of blisibimod in patients...
Apr 10, 2017 12:03 pm UTC| Business
LAS VEGAS, April 10, 2017 -- THC Therapeutics (OTC:THCT) is a publicly traded health and healing cannabis company. We are excited to announce that we have accomplished the first step of our stated plans for the growth...
Apr 10, 2017 12:04 pm UTC| Business
LAS VEGAS, April 10, 2017 -- THC Therapeutics (OTC:THCT) is a publicly traded health and healing cannabis company. We are excited to announce that we have accomplished the first step of our stated plans for the growth...